By Patrick Costello

Fresenius Medical Care AG (FME.XE) said Tuesday that its North America unit has invested an undisclosed sum in the Denver-based medical wearable startup BioIntelliSense.

The aim of the investment is to jointly create clinical pathways that alert clinicians to early-intervention needs, preventing complications and reducing unnecessary hospitalizations, the German health-care company said.

BioItelliSense is the developer of a data-services platform for continuous remote health monitoring, predictive analytics and algorithmic clinical insights, Fresenius said.

Fresenius will supply its expertise in advanced analytics and artificial intelligence to develop and deploy the platform with BioIntelliSense, it said.

The project supports Fresenius's goal of improving monitoring, interventions and outcomes for patients living with kidney disease and other chronic illnesses, it added.

Write to Patrick Costello at patrick.costello@dowjones.com.

(END) Dow Jones Newswires

July 09, 2019 10:33 ET (14:33 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Fresenius Medical Care (TG:FME)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Fresenius Medical Care Charts.
Fresenius Medical Care (TG:FME)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Fresenius Medical Care Charts.